BioCryst Pharma (BCRX) Tops Q3 EPS by 11c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.99 --0%
EPS Growth %: -13.3%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -13.3%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of $0.16, $0.11 better than the analyst estimate of $0.05. Revenue for the quarter came in at $159.1 million versus the consensus estimate of $162.97 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $590-600 million, versus the consensus of $626.1 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AeroVironment restates quarterly financials, citing $89M goodwill error
- American States Water completes $200 million ATM equity offering
- Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
